10-Q: Philip Morris International Reports Strong Q1 2024 Results Driven by Smoke-Free Products

Philip Morris International's first quarter 2024 results show a significant increase in revenue and earnings, driven by growth in smoke-free products and strategic pricing.

Summary

• Philip Morris International (PMI) reported a 9.7% increase in net revenues to $8.8 billion for the first quarter of 2024, compared to the same period in 2023.
• Excluding currency fluctuations, net revenues increased by 12.1%, primarily due to favorable pricing and volume/mix, particularly in heated tobacco units (HTUs) and ZYN nicotine pouches.
• Diluted earnings per share (EPS) rose to $1.38, a 7.8% increase from $1.28 in the first quarter of 2023.
• The company's operating income increased by 11.5% to $3.045 billion, with a 23.5% increase excluding currency impacts.
• PMI's total cigarette and HTU shipment volume increased by 3.1%, with HTU shipments up by 20.9% and cigarette shipments down by 0.4%.
• Oral smoke-free product volume increased by 40.0%, driven by nicotine pouches and snus.
• The company recorded pre-tax asset impairment and exit costs of $168 million, primarily related to restructuring the sourcing of IQOS products for the U.S. market and ceasing operations in Venezuela.
• PMI's effective tax rate for the quarter was 24.8%, up from 17.3% in the same period last year, impacted by deferred tax charges and fair value adjustments of equity securities.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and growth in key areas, particularly smoke-free products. However, there are some concerns about currency fluctuations, increased costs, and regulatory risks, which temper the overall sentiment.

Positives

• Strong revenue growth driven by smoke-free products and strategic pricing.
• Significant increase in HTU and oral smoke-free product volumes.
• Improved operating income, particularly when excluding currency fluctuations.
• Positive impact from pricing actions and volume/mix.
• Successful integration of Swedish Match business into existing regional structure.

Negatives

• Unfavorable currency movements negatively impacted net revenues and diluted EPS.
• Increased interest expense due to higher average debt levels and interest rates.
• Higher effective tax rate compared to the same period last year.
• Asset impairment and exit costs related to restructuring activities.
• Increased manufacturing costs and marketing and administration expenses.

Risks

• The company faces regulatory restrictions on tobacco and nicotine products, which could impact its ability to market and sell products.
• Excessive excise tax increases and discriminatory tax structures could negatively affect profitability.
• Illicit trade in tobacco and nicotine products poses a significant challenge.
• The company is subject to intense competition from other tobacco and nicotine product manufacturers.
• Pending and threatened litigation could have a material adverse effect on the company's financial results.
• The war in Ukraine and related sanctions could disrupt operations and supply chains.
• The company is exposed to credit risk and counterparty risk.
• Cybersecurity incidents and data breaches could disrupt operations and result in financial losses.
• The company may not fully realize the expected benefits from recent acquisitions.
• Changes in consumer preferences and economic conditions could impact demand for the company's products.

Future Outlook

PMI expects full-year 2024 net cash provided by operating activities of $10 billion to $11 billion at prevailing exchange rates, subject to year-end working capital requirements. The company also expects total cigarette, HTU and oral smoke-free product shipment volume growth of flat to +1% driven by smoke-free products. Nicotine pouch shipment volume in the U.S. is expected to be approximately 560 million cans.

Management Comments

• The company is actively delivering a smoke-free future and evolving its portfolio to include products outside of the tobacco and nicotine sector.
• PMI has invested over $12.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products.
• The Swedish Match acquisition is a key milestone in PMIs transformation to becoming a smoke-free company.
• The company is focused on commercializing smoke-free products and tailoring its strategy to specific markets.
• PMI is committed to conducting rigorous scientific assessments of its SFP platforms.

Industry Context

The announcement reflects the ongoing shift in the tobacco industry towards smoke-free alternatives, with PMI positioning itself as a leader in this transition. The results highlight the growing consumer acceptance of heated tobacco and oral nicotine products, while traditional cigarette sales continue to decline. The company's strategic focus on innovation and scientific substantiation aligns with broader industry trends towards harm reduction and regulatory compliance.

Comparison to Industry Standards

• PMI's 20.9% growth in HTU shipments significantly outpaces the overall cigarette market decline, indicating a strong performance in the heated tobacco category compared to competitors like British American Tobacco and Japan Tobacco, which also have heated tobacco offerings but may not be experiencing the same growth rates.
• The 40% increase in oral smoke-free product volume, driven by ZYN, demonstrates PMI's strong position in the nicotine pouch market, particularly in the U.S., where it competes with other oral nicotine brands but appears to be gaining market share.
• While PMI's overall revenue growth of 9.7% is robust, it's important to compare this against competitors' results to assess relative performance. For example, British American Tobacco's recent results may show different growth rates in specific categories or regions.
• The company's investment in R&D and scientific substantiation of its smoke-free products is a key differentiator, setting it apart from competitors who may not have the same level of scientific backing for their products. This is particularly relevant in the context of regulatory scrutiny and the need for modified risk tobacco product approvals.
• PMI's strategic decision to end its commercial relationship with Altria in the U.S. and take full control of IQOS commercialization is a significant move, setting it apart from competitors who may rely on partnerships for distribution in key markets. This move positions PMI to directly compete in the U.S. market, which is the largest smoke-free market globally.

Management Changes

Legal Proceedings

• The company is involved in various legal proceedings related to tobacco and nicotine products, including litigation in Canada and Nigeria.
• PMI is also facing litigation related to its oral nicotine products in the United States.
• The company is involved in a dispute with the Thai government regarding customs duties and excise taxes.
• PMI entered into a settlement agreement with Nicoventures Trading Limited, resolving patent infringement litigation related to heated tobacco and vapor products.

Related Party Transactions

• PMI has related-party transactions with Megapolis Group, EITA, UTC, TTI, and GPI, primarily for distribution, service fees, contract manufacturing, and license agreements.
• Transactions between PMI and RBH are considered related-party transactions from the date of deconsolidation.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance and growth in smoke-free products.
• Employees may be affected by restructuring activities and changes in compensation.
• Customers will have access to a wider range of smoke-free products.
• Suppliers may be impacted by changes in sourcing strategies.
• Creditors will be impacted by the company's debt levels and credit ratings.

Next Steps

• PMI will continue to focus on the commercialization and growth of its smoke-free products.
• The company will continue to invest in research and development to further substantiate the reduced risk profile of its smoke-free products.
• PMI will finalize the accounting for the reacquisition of IQOS commercialization rights in the U.S. in May 2024.
• The company will continue to monitor and comply with evolving regulations and trade restrictions.
• PMI will continue to assess the evolving situation in Russia and its impact on operations.

Key Dates

Keywords

Philip Morris International, smoke-free products, heated tobacco units, nicotine pouches, ZYN, IQOS, financial results, revenue growth, earnings per share, operating income, asset impairment, currency impact, tobacco industry, regulatory risks, Swedish Match, Vectura Fertin Pharma